We have located links that may give you full text access.
Diagnostic Value of Methylated Septin9 for Colorectal Cancer Detection.
Background: Methylated Septin9 ( mSEPT9 ) has been suggested as a reliable biomarker in colorectal cancer (CRC) detection. We aimed to determine the diagnostic value of mSEPT9 for CRC detection in Chinese patients. In addition, we compared the diagnostic efficacy of mSEPT9 to traditional screening method [fecal occult blood test (FOBT)] and two biomarkers [carcinoembryonic antigen (CEA) and carbohydrate antigen-199 (Ca-199)].
Methods: Overall 248 subjects including 123 patients with CRC and 125 controls were included. Plasma and fecal samples were collected for CEA, Ca-199, mSEPT9 , and FOBT tests. Sensitivity and specificity were calculated to evaluate the diagnostic efficacy of each method; receiver operating characteristic (ROC) curve was plotted for the assessment of diagnostic accuracy, and comparisons among FOBT, mSEPT9 , and the combination were assessed through area under the ROC curve (AUC).
Results: mSEPT9 achieved overall sensitivity and specificity of 61.8% [95% confidence interval (CI): 53.0-69.9%] and 89.6% (83.0-93.8%), respectively, with an AUC value of 0.757 (95% CI: 0.701-0.807), superior to FOBT [sensitivity: 61.4% (50.9-70.9%); specificity: 70.3% (59.1-79.5%); AUC: 0.658 (0.578-0.723)], CEA [sensitivity: 35.0% (27.1-43.7%); specificity: 62.6% (53.8-70.7%); AUC: 0.485 (0.411-0.559)], and Ca-199 [sensitivity: 17.9% (12.1-25.6%); specificity: 55.7% (48.9-64.1%); AUC: 0.353 (0.283-0.423)]. The combination of mSEPT9 and FOBT further improved sensitivity and AUC value of 84.1% (75.1-90.3%) and 0.807 (0.752-0.863), respectively, while specificity was declined to 62.2% (50.8-72.4%).
Conclusion: mSEPT9 demonstrated best diagnostic ability in CRC detection compared with FOBT, CEA, and Ca-199. The combination of mSEPT9 and FOBT further improved diagnostic sensitivity especially for early stage disease, which may provide a new approach for future CRC screening, though further investigations are warranted.
Methods: Overall 248 subjects including 123 patients with CRC and 125 controls were included. Plasma and fecal samples were collected for CEA, Ca-199, mSEPT9 , and FOBT tests. Sensitivity and specificity were calculated to evaluate the diagnostic efficacy of each method; receiver operating characteristic (ROC) curve was plotted for the assessment of diagnostic accuracy, and comparisons among FOBT, mSEPT9 , and the combination were assessed through area under the ROC curve (AUC).
Results: mSEPT9 achieved overall sensitivity and specificity of 61.8% [95% confidence interval (CI): 53.0-69.9%] and 89.6% (83.0-93.8%), respectively, with an AUC value of 0.757 (95% CI: 0.701-0.807), superior to FOBT [sensitivity: 61.4% (50.9-70.9%); specificity: 70.3% (59.1-79.5%); AUC: 0.658 (0.578-0.723)], CEA [sensitivity: 35.0% (27.1-43.7%); specificity: 62.6% (53.8-70.7%); AUC: 0.485 (0.411-0.559)], and Ca-199 [sensitivity: 17.9% (12.1-25.6%); specificity: 55.7% (48.9-64.1%); AUC: 0.353 (0.283-0.423)]. The combination of mSEPT9 and FOBT further improved sensitivity and AUC value of 84.1% (75.1-90.3%) and 0.807 (0.752-0.863), respectively, while specificity was declined to 62.2% (50.8-72.4%).
Conclusion: mSEPT9 demonstrated best diagnostic ability in CRC detection compared with FOBT, CEA, and Ca-199. The combination of mSEPT9 and FOBT further improved diagnostic sensitivity especially for early stage disease, which may provide a new approach for future CRC screening, though further investigations are warranted.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app